Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

1(25.0%)

Phase 2

1(25.0%)

N/A

1(25.0%)

Phase 4

1(25.0%)

4Total

Phase 3(1)

Phase 2(1)

N/A(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04856644Phase 3Active Not Recruiting

Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB

Role: collaborator

NCT04133987Phase 2Completed

Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan

Role: collaborator

NCT04384380Not ApplicableCompleted

Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19

Role: collaborator

NCT01002170Completed

Pharmacokinetic Study of Patients Who Undergo Cycloserine, a 2nd-line Antituberculosis Medicament

Role: collaborator

NCT00961337Phase 4Completed

Evaluation of a School-based Influenza Vaccination Program

Role: lead

All 5 trials loaded